South Korea Multiomics Market Size, Share, Growth, and Industry Analysis, By Omics Type (Genomics, Transcriptomics, Proteomics, Metabolomics), By Application (Drug Discovery and Development, Precision Medicine and Personalized Therapy, Biomarker Identification, Clinical Diagnostics) and Forecast, 2026-2034

South Korea Multiomics Market Trends

Single-cell profiling and integrated computational analysis reshape research workflows

High-throughput laboratories increasingly generate millions to billions of molecular measurements across DNA, RNA, proteins, metabolites, and epigenetic markers. Modern sequencing systems can process billions of reads per run, while single-cell experiments routinely evaluate thousands to tens of thousands of cells. This scale is accelerating the transition from isolated molecular assays toward integrated datasets capable of connecting genotype, expression, protein activity, and phenotype.

Technology demand is consequently shifting toward next-generation sequencing, high-resolution mass spectrometry, single-cell analysis, and multiomics integration platforms. Research programs increasingly combine 2–4 molecular layers rather than relying on a single assay, while pharmaceutical workflows can evaluate thousands of candidate biomarkers during discovery. Oncology, rare diseases, immunology, infectious diseases, and personalized therapeutics remain prominent demand areas.

South Korea Multiomics Market Drivers

Expansion of precision medicine and biopharmaceutical research accelerates integrated omics adoption

South Korea's biotechnology ecosystem is expanding its use of molecular profiling across drug discovery, translational research, and clinical investigation. Multi-layer studies can combine 2, 3, or more molecular datasets and analyze thousands of genes, proteins, or metabolites simultaneously. Improvements in sequencing throughput, mass-spectrometry sensitivity, cloud computing, and AI-assisted interpretation are reducing analytical bottlenecks, while research programs increasingly require datasets containing millions of molecular observations. These capabilities support faster biomarker screening and more granular patient stratification.

South Korea Multiomics Market Restraints

High analytical complexity and infrastructure requirements constrain broader laboratory adoption

Integrated studies may generate gigabytes to terabytes of raw information and require simultaneous processing of 2–7 molecular layers. Sequencing, mass spectrometry, sample preparation, storage, and bioinformatics can involve multiple specialized systems, while studies containing thousands of samples can substantially increase computational requirements. Data harmonization remains difficult because genomic, transcriptomic, proteomic, and metabolomic datasets differ in scale, noise, coverage, and reproducibility, creating technical barriers for smaller laboratories.

South Korea Multiomics Market Opportunities

AI-enabled integration creates opportunities across biomarkers and personalized therapeutics

Machine learning can evaluate thousands to millions of molecular variables and integrate 3–5 data modalities within unified analytical pipelines. Greater computing capacity and automated workflows are opening opportunities in oncology, pharmacogenomics, population research, nutrition, and infectious-disease surveillance. As sequencing costs decline and throughput increases into billions of reads, laboratories can expand cohort sizes while extracting more biological information from individual specimens, strengthening opportunities for software providers, analytical-service companies, and specialized research organizations.

Challenges in South Korea Multiomics Market

Standardization, interoperability, and reproducibility remain critical implementation challenges

Combining 2 or more omics layers introduces batch effects, missing values, different dynamic ranges, and complex normalization requirements. A single program may involve thousands of genes, proteins, metabolites, and clinical variables, requiring substantial storage and specialized computational expertise. Laboratories must also establish consistent sample collection and quality-control protocols, because relatively small variations in handling can propagate across multiple molecular datasets. These challenges increase requirements for interoperable platforms, standardized pipelines, and reproducible analytical frameworks.

South Korea Multiomics Market Segmentation

The industry is segmented by omics type, application, technology, offering, and end user. Genomics represents approximately 30.6% of the 2026 omics-type total, while Drug Discovery and Development contributes approximately 28.9% of application revenue. The structure highlights strong demand for integrated sequencing, mass spectrometry, bioinformatics, and molecular interpretation capabilities.

By Omics Type

Genomics is the largest category, increasing from USD 8.07 million in 2025 to USD 9.40 million in 2026 and USD 31.75 million by 2034, representing a 16.44% CAGR. Its 2026 contribution is approximately 30.6%. Proteomics reaches USD 19.10 million by 2034 at 16.45% CAGR, while transcriptomics reaches USD 18.01 million at 15.91%.

Metabolomics is the fastest-growing omics category at 17.10% CAGR, rising from USD 3.30 million in 2026 to USD 11.68 million by 2034. Lipidomics follows at 16.95% CAGR, while epigenomics records 16.89%. The overall omics-type total increases from USD 30.76 million to USD 103.95 million.

By Application

Drug Discovery and Development leads applications, expanding from USD 7.62 million in 2025 to USD 8.88 million in 2026 and USD 30.15 million by 2034 at 16.51% CAGR. It accounts for approximately 28.9% of the 2026 application total. Precision Medicine and Personalized Therapy reaches USD 20.08 million by 2034 at 16.17%.

Infectious Disease Surveillance is the fastest-growing application at 17.24% CAGR, reaching USD 5.61 million in 2034 from USD 1.57 million in 2026. Nutrigenomics follows at 17.05%, while Agriculture and Crop Research records 16.66%.

By Technology

Next-Generation Sequencing represents a foundational technology because sequencing workflows can generate millions to billions of reads and simultaneously characterize large molecular panels. Mass spectrometry supports high-throughput proteomic and metabolomic measurements, while single-cell analysis enables profiling across thousands of individual cells. Microarrays, Real-Time PCR, and integration platforms remain complementary technologies across targeted and discovery workflows.

Multiomics Integration Platforms are positioned for rapid adoption as laboratories combine 2–7 molecular layers and increasingly require unified pipelines for normalization, visualization, AI analysis, and interpretation. Technology-level revenue and CAGR values were not supplied in the mandatory dataset and are therefore not estimated.

By Offering

Software and Services are increasingly central as integrated experiments generate gigabyte-to-terabyte datasets requiring computational analysis, cloud storage, visualization, and specialist interpretation. Instruments remain critical for sequencing and mass spectrometry, while consumables support recurring sample preparation and assay workflows across thousands of laboratory runs.

Demand for software and services is reinforced by the requirement to harmonize 2 or more data modalities and process millions of molecular observations. Offering-level market values and CAGRs were not provided in the supplied tables; consequently, no unsupported numerical allocation is applied.

By End User

Pharmaceutical and Biotechnology Companies constitute a major adoption group because integrated molecular profiling supports target discovery, biomarker development, patient stratification, and therapeutic research. Academic and Research Institutions also process thousands of samples and increasingly combine 2–4 omics layers in systems-biology and translational programs.

Contract Research Organizations, Hospitals and Clinics, and Government and Public Health Agencies broaden the addressable user base. Their requirements range from multi-thousand-sample research programs to surveillance and clinical investigations. End-user revenue and CAGR figures were not supplied and are therefore not extrapolated.

South Korea Multiomics Market Outlook

Seoul Capital Area

The Seoul Capital Area is the principal national research and commercialization cluster, concentrating universities, tertiary hospitals, pharmaceutical organizations, biotechnology ventures, and computational research capabilities. Nationally, the market reaches USD 30.76 million in 2026 and USD 103.95 million by 2034. Genomics contributes approximately 30.6% of 2026 omics revenue, while drug discovery represents about 28.9% of application revenue.

Daejeon and Central South Korea

Daejeon and the central research corridor contribute through government-supported science infrastructure, universities, biotechnology laboratories, and research institutes. Across South Korea, proteomics contributes approximately 18.4% of 2026 omics revenue and transcriptomics about 18.0%, supporting demand for sequencing, mass spectrometry, and integrated computational analysis. Subnational revenue shares and production volumes were not supplied and are not estimated.

Busan and Southeastern South Korea

Busan and southeastern provinces support clinical, university, healthcare, and biotechnology research activity. National Clinical Diagnostics revenue increases from USD 3.09 million in 2026 to USD 10.12 million by 2034 at 16.01% CAGR, while Biomarker Identification advances from USD 4.60 million to USD 15.39 million at 16.28%. County-level financial contributions were not provided in the mandatory dataset.

Top players in South Korea Multiomics Market

• Samsung Biologics
• Macrogen
• GC Genome
• Theragen Bio
• Bioneer
• Illumina
• Thermo Fisher Scientific
• Agilent Technologies
• QIAGEN
• Bruker
• Waters Corporation
• SCIEX
• 10x Genomics
• Bio-Rad Laboratories
• Pacific Biosciences

Top two companies

• Macrogen

The company is positioned within South Korea's genomics and sequencing ecosystem, with capabilities relevant to high-throughput genomic analysis and research services. Genomics is the country's largest supplied omics category at USD 9.40 million in 2026, approximately 30.6% of total omics-type revenue, and is projected to reach USD 31.75 million by 2034 at 16.44% CAGR. This environment provides a strong addressable foundation for sequencing and integrated analytical services. Verified company-specific market share percentages were not supplied, so no unsupported share estimate is assigned.

• Theragen Bio

Theragen Bio is positioned around genomic analysis, bioinformatics, precision-medicine research, and data-driven biological interpretation. Precision Medicine and Personalized Therapy represents USD 6.05 million in 2026 and is projected to reach USD 20.08 million by 2034 at 16.17% CAGR. Biomarker Identification advances from USD 4.60 million to USD 15.39 million at 16.28%, providing an additional commercially relevant application base. No verified company-level percentage share was supplied in the mandatory dataset; therefore, a numerical competitive share is not fabricated.

Recent Developments in South Korea Multiomics Market

• 2026: Integrated sequencing and computational workflows continued gaining relevance as the national industry reached USD 30.76 million, with genomics contributing approximately 30.6% of omics-type revenue.
• 2025: The national industry stood at approximately USD 26.42–26.43 million across the supplied segmentation tables, establishing the base for double-digit expansion through 2034.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, 2022–2024 as the historical period, and 2026–2034 as the forecast horizon. Mandatory supplied numerical tables were treated as the primary quantitative source. The 2026 national value of USD 30.76 million, 2034 value of USD 103.95 million, and 16.52% CAGR anchor the forecast. Segment contributions were calculated directly from supplied totals; for example, USD 9.40 million of genomics divided by USD 30.76 million equals approximately 30.6%. Values unavailable in the source dataset—including technology, offering, end-user, subnational, production, and company-share figures—were not fabricated.